Circulating tumor cells (CTCs) are specialized rare cells, which have been shed from a primary solid tumor of the body and circulate in the vasculature system of the body, eventually causing metastasis. CTCs act as the seeds for successive development of additional metastatic tumors in distant organs, which is liable for the majority of cancer-related deaths. On the other hand, these fatal rare cells are capable of providing useful information of cancer patients, since their monitoring and detection is valuable for predicting the response to treatment and prognosis as well as staging of the disease. These rare cells are found both in the bone marrow and in peripheral blood of the body. However, the CTCs found in the blood usually have a short survival time as compared to CTCs found in the bone marrow, which makes the analysis of blood sample for CTCs more specific, thus known as “liquid biopsy”. Therefore, detection of CTCs during the progression of the tumor provides a prognostic value of the tumor progression as well as evaluates the efficacy of therapeutic intervention and provides necessary information for developing personalized medicines.
The primary factors driving the growth of the CTCs prognostic technologies market are increasing demand for diagnostic and prognostic technologies coupled with high incidence and prevalence rates of cancer. Furthermore, colossal application scope of these technologies and patient safety are also some of the factors driving the growth of the CTCs prognostic technologies market. Additionally, substantial cost benefit ratio of these technologies and wide use in therapeutic monitoring are some of the other significant factors that are expected to fuel the growth of the CTCs technologies globally. However, some of the important factors that are restraining the growth of this market are high pricing associated with the technologies and stringent regulatory policies.
The CTCs prognostic technologies market is categorized based on technology and applications. The technology market has been further segmented into tumor cell enrichment and tumor cell detection. Moreover, the tumor cell enrichment market is further segmented into filtration, centrifugation and immunomagnetic methods, among which immunomagnetic methods accounted for the largest market due to commercial availability and high adoption rate for these techniques. Moreover, the tumor cell detection market is further bifurcated into molecular methods and optical methods. Furthermore, these technologies are usually applied in breast cancer, prostate cancer and colorectal cancer as well as other types of cancer (e.g. lung cancer, ovarian cancer and pancreas cancer); among which, breast cancer is expected to witness the highest growth during the forecast period. This growth can be attributed to the increasing prevalence rate of breast cancer and high adoption rate. However, it is also expected that other types of cancer (e.g. colorectal, lung, pancreas and ovarian) will account for a significant share of the market due to their rising prevalence rates and increasing research and development activities for developing personalized medicine.
North America is the largest market for CTCs prognostic technologies owing to the high prevalence and incidence rate of cancer as well as high adoption rate for advanced prognostic technologies. However, low commercial availability of these technologies and high development cost of the technologies are some of the factors that have led to the sluggish growth of this market. However, other regions such as Asia-Pacific is also estimated to show an appreciable growth rate owing to the expected rise in various types of cancer coupled with high research and development initiatives and growing adoption rate for advanced therapeutic monitoring technologies.
AdnaGen AG, Epic Sciences, Inc., Fluxion Biosciences, Inc., Silicon Biosystems, S.p.A., Rarecells USA, Inc., Veridex, LLC and Vitatex Inc. are major companies leading the circulating tumor cells (CTCs) prognostic technologies market.
This report provides the market analysis for various technologies and applications used for the enrichment and detection of circulating tumor cells (CTCs). The stakeholders of this report include companies and research institutes involved in the production of prognosis kits and research and development activities related to circulating tumor cells technologies as well as the new entrants who wish to enter this market.
The market overview section of the report analyzes the market dynamics and trends such as drivers, restraints and opportunities that would affect the current and future scenario of the CTC technologies market. Porter’s five forces analysis is included in this study to provide thorough analysis about the competitive status, and market attractiveness analysis has been added to describe the market outlook in different geographies. Event impact analysis is provided in this report for a brief understanding of the technological advancements that have taken place in the past and are planned for the future. Value chain analysis of the market is discussed to recognize value-creating activities from a number of processes, which can provide CTC technology a competitive advantage over other technologies.
Circulating tumor cells (CTCs) are specialized rare cells detached from primary tumors and disseminated in the vasculature system of the body, eventually causing metastasis. CTCs are composed of cells that act as seeds for successive development of additional metastatic tumors in essential distant organs, which is a cause of majority of cancer-related deaths. These CTCs are not easily detected, as these are present in less numbers in the blood stream. Tumors shed nearly 1 million circulating tumor cells (CTCs) per gram of tumor tissue. The global circulating tumor cells (CTCs) prognostic technologies market is segmented based on technologies and applications. Moreover, the technology market is further segmented into tumor cell enrichment and tumor cell detection.
Based on tumor cell enrichment technologies, the report includes market analysis of filtration, centrifugation and immunological & immunomagnetic enrichment methods. Based on tumor cell detection technologies, the market is segmented into molecular methods and optical methods. Furthermore, based on the applications, the CTC prognostic technologies market is segmented into breast cancer, colorectal cancer, prostate cancer and others (lung, ovarian and pancreatic cancer). Market forecast for all these segments has been provided in the report for the period 2012 to 2020 in terms of USD million, along with CAGR for the forecast period 2014 to 2020, considering 2013 as the base year.
Geographically, the global CTCs prognostic technologies market has been segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World (RoW). North America is the leading market for CTCs prognostic technologies owing to the high adoption rate for advanced prognostic technologies as well as high prevalence and incidence rate of cancer. However, low commercial availability of these technologies and stringent regulatory approvals of these technologies are some of the factors that have led to the sluggish growth of this market. However, other regions such as Asia-Pacific is also expected to show a substantial growth rate owing to the increasing base of cancer patients coupled with high government support and growing adoption rate for advanced therapeutic monitoring technologies. The market revenue of CTC technologies for 2012 and 2020 and forecast from 2014 to 2020 in respective regions in terms of USD million and value percentage, respectively, is explained in this section of the report.
The report concludes with the profiles of key players in the CTC technologies market. Major companies profiled in this report include AdnaGen AG, Advanced Cell Diagnostics, Inc., AVIVA BioSciences Corporation, Celula, Inc., Epic Sciences, Inc., Fluxion Biosciences, Inc., Rarecells USA, Inc., Silicon Biosystems, S.p.A., Veridex, LLC, Vitatex, Inc. and others.
The global circulating tumor cells (CTCs) prognostic technologies market is segmented as follows:
Circulating Tumor Cells (CTCs) Prognostic Technologies Market, by Technology
Tumor Cell Enrichment
- Immunological & Immunomagnetic Methods
Tumor Cell Detection
- Molecular Methods
- Optical Methods
Circulating Tumor Cells (CTCs) Prognostic Technologies Market, by Applications
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Others (Lung, Ovarian and Pancreatic Cancer)